BrainCo Plans an 'Electronic GLP-1' Wearable to Curb Appetite

BrainCo, a Chinese brain-computer interface company based in Hangzhou, says it will launch a wearable that suppresses appetite through brain stimulation within two to three years, initially in China. Founding partner Nyx He described the planned product at the Bloomberg Tech London event as an "electronic version of GLP-1" obesity drugs such as Wegovy and Zepbound.

The claim is the fact. The evidence is, so far, not public. The company has disclosed no technical specifications, no clinical results and no precise mechanism for how the wearable would regulate appetite. What it has disclosed is a timeline and a market.

What does the device actually do?

According to the company, the device will use BrainCo's non-invasive BCI technology to stimulate specific brain signals and suppress appetite without medication. BrainCo's existing platform reads neural signals through the skin and translates them into commands for external devices. Whether appetite circuits can be reached that way, and with what fidelity, remains the open question the company has not yet answered.

He told Bloomberg that BrainCo aims to bring the product to market within two or three years, targeting China first and the United States potentially after. The company is weighing different commercialisation routes, including separate medical and consumer versions of the device.

For now, this is investigational work with a commercial timetable attached. Nothing in the announcement indicates regulatory clearance anywhere, and clinicians should read the two-to-three-year figure as a company target rather than a pathway milestone.

Who is BrainCo?

The firm has built its business on non-invasive interfaces, not implanted hardware. Its current portfolio includes:

• BCI-enabled headsets marketed for neurological conditions including autism, ADHD and insomnia
• Prosthetic hands that let amputees control lifelike fingers with brain signals, fine enough for playing the piano or practising calligraphy
• Robotic hands supplied to China's humanoid robotics industry

He indicated BrainCo could eventually explore invasive technologies involving implanted devices. That would be a departure for a company whose identity, and regulatory exposure, has rested on hardware that stays outside the skull.

Can a Chinese neurotech firm sell in the US?

The expansion plans arrive amid proposed US restrictions on investment in Chinese neurotechnology and broader geopolitical scrutiny of the sector. He said the company continues to see "great market acceptance" for its prosthetic hands in the US, and declined to comment on listing timing or future fundraising.

The money behind the ambition is substantial. BrainCo reportedly raised 2 billion yuan, roughly $299.8 million, earlier in 2026, and Bloomberg reported in January that the company had confidentially filed for a Hong Kong initial public offering.

BrainCo is not alone

Another Chinese startup, Gestala, is pursuing non-invasive neuromodulation from a different angle: an ultrasound-based system to read brain activity and stimulate neural circuits. Founded in January, Gestala has raised 570 million yuan, about $85.4 million, across two funding rounds. Its initial target is chronic pain, with stated plans to explore depression, obsessive-compulsive disorder and stroke.

Gestala's targets are conventional neuromodulation territory. BrainCo's is not. Obesity treatment belongs to metabolic pharmacology, where GLP-1 receptor agonists from Novo Nordisk and Eli Lilly have reshaped the market by mimicking hormones involved in appetite regulation.

What does this change for practice?

Nothing yet, and that is the honest verdict. No scalp EEG protocol, no stimulation parameter set, no trial data and no regulatory filing specific to this device exists in the public record. The story matters because a funded, IPO-bound BCI company has decided that appetite is a neural target worth commercial investment, and has put a date on it.

If the wearable reaches Chinese clinics within the stated window, neurophysiology labs may inherit a new class of patient questions about externally stimulated appetite circuits. Until specifications and human data appear, the electronic GLP-1 remains a headline with a hardware problem to solve.